Form 4: Eli Lilly CEO Ricks Exercises RSUs, Sells Shares for Tax

Eli Lilly & Co's President, Chair, and CEO, David A. Ricks, acquired common stock through restricted stock unit exercise and subsequently sold shares for tax withholding purposes.

Summary

• David A. Ricks, President, Chair, and CEO of Eli Lilly & Co, engaged in transactions involving the company's common stock on February 1, 2026.
• Ricks acquired 31,932 shares of common stock through the exercise of restricted stock units at a price of $0 per share.
• Concurrently, Ricks disposed of 14,296.654 shares of common stock at a price of $1,037.15 per share to cover tax withholding obligations related to the RSU exercise.
• Following these transactions, Ricks directly beneficially owns 532,801.513 shares of common stock.
• Ricks also holds indirect beneficial ownership through various trusts, including the David A. Ricks 2025 GRAT (6,685 shares), David A. Ricks 2022 GRAT (54,117 shares), a separate Trust (300 shares), David A. Ricks SLAT (68,656 shares), and a 401(k) plan (7,311.26 shares).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction related to equity compensation vesting and tax obligations, which is generally neutral but reflects the CEO's continued equity stake.

Positives

• The acquisition of 31,932 shares through Restricted Stock Unit (RSU) exercise indicates the vesting of previously granted equity compensation, aligning management's interests with shareholders.

Negatives

• The disposition of 14,296.654 shares, valued at approximately $14.8 million (14,296.654 * $1,037.15), represents a reduction in direct beneficial ownership, although it was for tax withholding purposes.

Risks

• No specific risks are mentioned in this Form 4 filing, which primarily reports insider transactions.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance. It is a historical report of insider transactions.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving equity compensation and tax-related sales, are common occurrences for senior executives in the pharmaceutical industry. The exercise of RSUs and subsequent sale for tax purposes by Eli Lilly's CEO is a routine event and does not inherently signal a change in company fundamentals or strategic direction, unlike open market purchases or sales.

Comparison to Industry Standards

• The exercise of Restricted Stock Units (RSUs) and subsequent "sell-to-cover" for tax obligations is a standard practice for executives across industries, including major pharmaceutical companies like Pfizer, Merck, and Johnson & Johnson.
• The reported transaction price of $1,037.15 per share for the disposition aligns with Eli Lilly's recent stock performance, which has seen significant growth, outperforming many peers in the pharmaceutical sector due to strong performance of drugs like Mounjaro and Zepbound.
• The substantial direct and indirect beneficial ownership of over 530,000 shares by CEO David A. Ricks remains significant, comparable to the equity holdings of CEOs at other large-cap pharmaceutical companies, demonstrating continued alignment with shareholder interests despite the tax-related sale.

Stakeholder Impact

• Shareholders: The transaction is a routine part of executive compensation and tax planning. It does not indicate a change in the company's operational or financial performance. The CEO retains a substantial equity stake, maintaining alignment with shareholder interests.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the exercise of restricted stock units and a subsequent sale of shares to cover tax obligations. Such transactions are common for executives and do not typically signal a change in the company's fundamental outlook or the executive's confidence in the company. Therefore, it provides no new information that would warrant a change from a "hold" recommendation based solely on this filing. Investors should continue to evaluate Eli Lilly based on its operational performance, pipeline, and market position.

Keywords

Eli Lilly, LLY, David A. Ricks, Insider Trading, Form 4, Restricted Stock Units, Equity Compensation, Stock Sale, Tax Withholding